Streetbeat News

Regulatory

MNMD

Mind Medicine (MindMed) Inc (NASDAQ:MNMD) announced the upcoming presentation of preclinical data of MM-402, its proprietary form of the R-enantiomer of 3,4-Methylenedioxymethamphetamine (MDMA), in a model for autism spectrum disorder (ASD) at the 36th Annual ECNP Congress. The company plans to initiate its first clinical trial of MM-402 in Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 11:31 am

BABA

FXI

KWEB

Alibaba Group Holding Limited (BABA) stock is trading lower in line with the broader indexes iShares China Large-Cap ETF (FXI) and KraneShares Trust KraneShares CSI China Internet ETF (KWEB). The U.S. administration plans to revise regulations restricting the export of AI chips and chipmaking tools to China, which is part of a broader strategy to stabilize U.S.-China relations. Despite U.S. chip sanctions, Alibaba has launched a new AI model and is planning separate IPOs for its different units.

Portfolio Pulse from Anusuya Lahiri

October 03, 2023 | 11:30 am

RNLX

Renalytix has announced that the Centers for Medicare & Medicaid Services has published the price for the company's FDA-authorized KidneyIntelX.DKD test on the Nationwide Clinical Laboratory Fee Schedule at $950.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 11:12 am

RDHL

Redhill Biopharma announced that its drug Opaganib showed a statistically significant increase in survival time at a 150 mg/kg twice daily dose in an Ebola Virus study conducted by the United States Army Medical Research Institute of Infectious Diseases.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 11:06 am

CYN

Cyngn, a company specializing in autonomous vehicle and driving solutions, has been granted US patents for its same-loop adaptive simulation approach.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 11:04 am

F

GM

STLA

VWAGY

President Biden's proposal to increase fuel efficiency norms by 2032 could lead to penalties of $6.5 billion for General Motors (GM), $3 billion for Stellantis (STLA), and $1 billion each for Ford (F) and Volkswagen (VWAGY). The American Automotive Policy Council, representing these companies, has expressed concerns about the Department of Energy's plans to alter the Petroleum Equivalency Factor, which could lead to higher compliance costs for U.S. carmakers.

Portfolio Pulse from Shivani Kumaresan

October 03, 2023 | 10:52 am

ADRT

Ault Disruptive Technologies Corporation, a special purpose acquisition company, has announced that the NYSE American has accepted its business plan to regain compliance with the Exchange's continued listing standards. The company was previously notified of its non-compliance with the standards, which require a listed company to maintain a minimum of 200,000 shares publicly held and a minimum of 300 public stockholders on a continuous basis.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 10:36 am

GM

A self-driving Cruise car was involved in an accident that left a pedestrian severely injured in San Francisco. The woman was reportedly hit by a human-driven vehicle before being struck by the autonomous vehicle. Cruise, a unit of General Motors Co (NYSE:GM), stated that the car was in autonomous mode with no passengers and stopped immediately after the impact. The San Francisco Police Department is investigating the incident.

Portfolio Pulse from Benzinga Neuro

October 03, 2023 | 9:20 am

FTTUSD

A class-action lawsuit has been filed against Binance and its CEO, Changpeng Zhao, accusing them of activities that led to the downfall of rival exchange FTX. The lawsuit alleges that Binance and Zhao violated federal and Californian laws concerning unfair competition, and sought to establish a monopoly in the crypto market by harming FTX. The plaintiff points to social media posts made by Zhao and Binance's decision to liquidate its FTX token (CRYPTO: FTT) holdings as contributing factors to FTX's collapse.

Portfolio Pulse from Benzinga Neuro

October 03, 2023 | 9:12 am

CALT

Calliditas Therapeutics AB has announced that its partner STADA Arzneimittel AG has submitted a request to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to convert the conditional marketing authorization for Kinpeygo®, a treatment for primary IgA nephropathy (IgAN), to standard, or 'full', marketing authorization.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 8:24 am